Gene Editing & Screening

Ralph Garippa

Director

The Gene Editing & Screening Core Facility (GES Core) brings together complementary technologies aimed at interrogating cancer biology and identifying molecular vulnerabilities of cancer cells. The GES Core expertly enables all aspects of state-of-the-art technologies in RNA interference and CRISPR-Cas9 mediated gene editing for functional genomics initiatives.

In parallel, towards the identification of chemical probes which influence cancer phenotypes, the GES Core maintains and operates a workstation-based small molecule high throughput screening (HTS) facility using space- and cost-efficient approaches and a multi-pronged, targeted chemical library (I) for chemogenomic studies, (II) to phenocopy new molecular targets with pharmacological agents and (III) to enable bona fide chemical probe and early drug discovery in oncology. Moreover, considering that the microscopy has provided the morphological underpinning to the study of cancer biology, therefore the GES Core offers state-of-the-art automated arrayed 2D/3D laser line confocal imaging using high content screening & and analysis (HCS/HCA) tools.